Medicover (OM:MCOV B) Stock Faces Rich P/E As Margins Improve To 3.4%

Medicover (OM:MCOV B) has put fresh numbers on the table for Q2 2026, reporting revenue of €640.4 million and basic EPS of €0.16 as investors weigh the latest move in margins and profitability. The company has seen revenue range from €596.7 million in Q2 2025 to €640.4 million in Q2 2026, while quarterly EPS has moved between €0.13 and €0.16 across the same period, giving a clearer read on how the earnings line is tracking alongside top line expansion. With trailing net profit margins at 3.4% and earnings expectations pointing higher, this set of results keeps the focus firmly on how efficiently Medicover is converting its growing revenue base into profit.

See our full analysis for Medicover.

With the latest figures in hand, the next step is to compare Medicover’s reported growth and margins with the dominant narratives investors have been using to frame the stock, and to consider where those views might need to be updated.

See what the community is saying about Medicover

Margins and profit reach 3.4% on trailing basis

• On a trailing 12 month view, Medicover generated €84.9 million of net income on €2.5b of revenue, which works out to a 3.4% net profit margin compared with 1.9% a year earlier.
• Supporters of the bullish view point to this margin shift as evidence that earnings can scale, yet the current basic EPS of about €0.56 on a trailing basis still has a long way to go before it reaches the bullish narrative’s 2029 earnings assumptions. Investors therefore need to judge how repeatable these recent gains look rather than assuming the current trajectory continues in a straight line.
  • Trailing EPS of €0.56 and net income of €84.9 million are well below the bullish case that talks about earnings of more than €200 million several years out, which would require sustained improvement from today’s 3.4% margin.
  • The move from a 1.9% to 3.4% margin does heavily support the idea that operational leverage is starting to show up in the numbers, but it does not yet prove that margins can reach the 6% plus levels implied in some bullish expectations.

Bulls argue that Medicover's faster profit growth and improving margins could justify a much stronger long run earnings story than the headline figures alone suggest, so if you want to see how that thesis is built from the ground up, check out the 🐂 Medicover Bull Case

Revenue trend supports 24.2% earnings growth story

• Quarterly revenue has stepped from €578.1 million in Q1 2025 to €640.4 million in Q2 2026, and analysts are expecting about 10.8% annual revenue growth and roughly 24.2% annual earnings growth over the next three years.
• Analysts’ consensus view highlights steady demand for Medicover’s healthcare and diagnostics services. This recent run of quarterly revenue in the €578 million to €640 million range, alongside trailing 12 month earnings growth of 95.6%, aligns with the idea that the business model can support both higher volumes and improving profitability if current conditions hold.
  • The trailing 12 month revenue base of €2.5b gives a larger platform for any future percentage growth to translate into meaningful euro amounts, which is central to the consensus narrative that sees earnings moving well ahead of the €84.9 million reported over the last year.
  • At the same time, the move from Q1 2025 revenue of €578.1 million to Q2 2026 revenue of €640.4 million shows how incremental capacity additions and acquisitions feed into the top line, which is an important building block for the long term growth stories on both the bullish and consensus sides.

Valuation premium and interest cover test the bearish case

• Medicover trades on a P/E of 36.6x against a European Healthcare average of 20.3x and a peer average of 23x. The supplied data also show that interest payments are not well covered by earnings and a DCF fair value of about SEK633.18 compared with the current share price of SEK226.50.
• Critics in the bearish camp argue that high leverage and integration risk could strain profitability, and the combination of a premium P/E plus weak interest coverage supports those concerns even though the provided DCF fair value is materially above the share price. This gives investors two very different reference points to weigh.
  • The P/E gap, at 36.6x versus industry and peer levels in the low 20s, means a lot of future earnings progress is already reflected in the multiple, which is what bears focus on if margins or growth were to fall short of expectations.
  • Alongside that, the note that interest costs are not well covered by current earnings underlines balance sheet sensitivity. Even with a DCF fair value of about SEK633.18 implying upside from SEK226.50, investors still have to factor in the financial risk that weaker operating performance would pose.

Skeptics warn that Medicover's rich P/E and weak interest cover leave little room for disappointment, so if you want to see how the cautious narrative stacks these risks, take a look at the 🐻 Medicover Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Medicover on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mixed signals around Medicover, do you feel the risk reward balance lines up with your expectations, or not quite yet? Take a moment to review the full set of risks and rewards and decide how comfortable you are with the trade off using the 3 key rewards and 1 important warning sign

See What Else Is Out There

Medicover carries a rich 36.6x P/E, relies on a 3.4% net profit margin, and faces concerns over weak interest cover relative to its financial obligations.

If that mix of a premium valuation and balance sheet pressure feels uncomfortable, you could quickly compare it with companies screened for stronger finances using the solid balance sheet and fundamentals stocks screener (420 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com